| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Prevention |
Authors' Affiliations: 1 Arizona Cancer Center, The University of Arizona, Tucson, Arizona; 2 Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland; and 3 Mitsui Norin Co., Ltd., Shizuoka, Japan
Requests for reprints: H-H. Sherry Chow, Arizona Cancer Center, The University of Arizona, Tucson, AZ 85724. Phone: 520-626-3358; Fax: 520-626-5348; E-mail: schow{at}azcc.arizona.edu.
Purpose: Green tea has been shown to exhibit cancer-preventive activities in preclinical studies. Its consumption has been associated with decreased risk of certain types of cancers in humans. The oral bioavailability of the major green tea constituents, green tea catechins, is low, resulting in systemic catechin levels in humans many fold less than the effective concentrations determined in in vitro systems. We conducted this clinical study to test the hypothesis that the oral bioavailability of green tea catechins can be enhanced when consumed in the absence of food.
Experimental Designs: Thirty healthy volunteers were randomly assigned to one of the following doses of Polyphenon E (a decaffeinated and defined green tea catechin mixture): 400, 800, or 1,200 mg, based on the epigallocatechin gallate content (10 subjects per dose group). After an overnight fast, study participants took a single dose of Polyphenon E with or without a light breakfast, which consisted of one or two 4-oz muffins and a glass of water. Following a 1-week wash-out period, subjects were crossed over to take the same dose of Polyphenon E under the opposite fasting/fed condition. Tea catechin concentrations in plasma and urine samples collected after dosing were determined by high-pressure liquid chromatography analysis.
Results: Consistent with previous reports, epigallocatechin gallate and epicatechin gallate were present in plasma mostly as the free form, whereas epicatechin and epigallocatechin were mostly present as the glucuronide and sulfate conjugates. There was >3.5-fold increase in the average maximum plasma concentration of free epigallocatechin gallate when Polyphenon E was taken in the fasting condition than when taken with food. The dosing condition led to a similar change in plasma-free epigallocatechin and epicatechin gallate levels. Taking Polyphenon E in the fasting state did not have a significant effect on the plasma levels of total (free and conjugated) epigallocatechin, but resulted in lower plasma levels of total epicatechin. Urinary epigallocatechin gallate and epicatechin gallate levels were very low or undetectable following Polyphenon E administration with either dosing condition. Taking Polyphenon E under the fasting state resulted in a significant decrease in the urinary recovery of total epigallocatechin and epicatechin. Polyphenon E administered as a single dose over the dose range studied was generally well-tolerated by the study participants. Mild and transient nausea was noted in some of the study participants and was seen most often at the highest study agent dose (1,200 mg epigallocatechin gallate) and in the fasting condition.
Conclusions: We conclude that greater oral bioavailability of free catechins can be achieved by taking the Polyphenon E capsules on an empty stomach after an overnight fast. Polyphenon E up to a dose that contains 800 mg epigallocatechin gallate is well-tolerated when taken under the fasting condition. This dosing condition is also expected to optimize the biological effects of tea catechins.
Key Words: Oral bioavailability • Green tea catechins • Food effect • Doing condition
This article has been cited by other articles:
|
|
 |
|
  E. P. Moiseeva and M. M. Manson Dietary Chemopreventive Phytochemicals: Too Little or Too Much? Cancer Prevention Research, July 1, 2009; 2(7): 611 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Shah, D. J. Kuhn, and R. Z. Orlowski Bortezomib and EGCG: no green tea for you? Blood, June 4, 2009; 113(23): 5695 - 5696. [Full Text] [PDF]
|
|
|
|
|
|
E. B. Golden, P. Y. Lam, A. Kardosh, K. J. Gaffney, E. Cadenas, S. G. Louie, N. A. Petasis, T. C. Chen, and A. H. Schonthal Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors Blood, June 4, 2009; 113(23): 5927 - 5937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Bode and Z. Dong Epigallocatechin 3-Gallate and Green Tea Catechins: United They Work, Divided They Fail Cancer Prevention Research, June 1, 2009; 2(6): 514 - 517. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frank, T. W. George, J. K. Lodge, A. M. Rodriguez-Mateos, J. P. E. Spencer, A. M. Minihane, and G. Rimbach Daily Consumption of an Aqueous Green Tea Extract Supplement Does Not Impair Liver Function or Alter Cardiovascular Disease Risk Biomarkers in Healthy Men J. Nutr., January 1, 2009; 139(1): 58 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Anderson, C. Goodin, Y. Zhang, S. Kim, R. D. Estensen, T. S. Wiedmann, P. Sekar, C. R. Buncher, J. C. Khoury, J. R. Garbow, et al. Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice Carcinogenesis, August 1, 2008; 29(8): 1594 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Henning, J. J. Choo, and D. Heber Nongallated Compared with Gallated Flavan-3-ols in Green and Black Tea Are More Bioavailable J. Nutr., August 1, 2008; 138(8): 1529S - 1534S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Isaacs, G. Y. Wen, W. Xu, J. H. Jia, L. Rohan, C. Corbo, V. Di Maggio, E. C. Jenkins Jr., and S. Hillier Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus Antimicrob. Agents Chemother., March 1, 2008; 52(3): 962 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Khuri and D. M. Shin Head and Neck Cancer Chemoprevention Gets a Shot in the Arm J. Clin. Oncol., January 20, 2008; 26(3): 345 - 347. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-H. S. Chow, I. A. Hakim, D. R. Vining, J. A. Crowell, M. E. Tome, J. Ranger-Moore, C. A. Cordova, D. M. Mikhael, M. M. Briehl, and D. S. Alberts Modulation of Human Glutathione S-Transferases by Polyphenon E Intervention Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1662 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Kang, J. H. Lee, C. K. Song, H. D. Han, B. C. Shin, S. I. Pai, C.-F. Hung, C. Trimble, J.-S. Lim, T. W. Kim, et al. Epigallocatechin-3-Gallate Enhances CD8+ T Cell-Mediated Antitumor Immunity Induced by DNA Vaccination Cancer Res., January 15, 2007; 67(2): 802 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H-H. S. Chow, I. A. Hakim, D. R. Vining, J. A. Crowell, C. A. Cordova, W. M. Chew, M.-J. Xu, C.-H. Hsu, J. Ranger-Moore, and D. S. Alberts Effects of Repeated Green Tea Catechin Administration on Human Cytochrome P450 Activity Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2473 - 2476. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
